Abstract

Background: Observational studies that have supported the role of the leptin level in schizophrenia (SCZ) risk are conflicting. Therefore, we performed a two-sample Mendelian randomization (MR) analysis to investigate whether the circulating leptin and soluble plasma leptin receptor (sOB-R) levels play a causal role in SCZ risk.Methods: We first selected five independent single-nucleotide polymorphisms (SNPs) associated with the circulating leptin level and three independent SNPs associated with the sOB-R level from two genome-wide association studies (GWASs) of European individuals. Then, we extracted their associations with SCZ using a large-scale GWAS that consisted of 40,675 patients with SCZ and 64,643 controls of European ancestry. We performed an MR analysis using the inverse variance-weighted (IVW) method to examine the causal effect of leptin on SCZ risk. Moreover, we performed sensitivity analyses to verify our MR results using the weighted median and MR-Egger methods.Results: According to the IVW method, genetically predicted circulating leptin levels were not associated with SCZ risk (OR = 1.98, for per 1-SD unit increase in leptin level; 95% CI, 0.87–4.53; p = 0.10). In addition, the sOB-R level showed no causal effect on the SCZ risk using IVW (OR = 0.98 for per 1-SD unit increase in sOB-R level; 95% CI, 0.97–1.00; p = 0.06). Our sensitivity analysis results confirmed our MR findings.Conclusions: By estimating the causal effect of leptin on SCZ risk using the MR methods, we identified no effect of genetically predicted circulating leptin or the sOB-R level on SCZ. As such, our study suggests that leptin might not be a risk factor for SCZ.

Highlights

  • Schizophrenia (SCZ) is a major mental disease that represents a leading cause of impairment and burden worldwide [1]

  • For the five single-nucleotide polymorphisms (SNPs) associated with the circulating leptin level, we removed the SNP for being palindromic with intermediate allele frequencies

  • Using the four retained SNPs, we found that the genetically predicted leptin level had a significant effect on the SCZ risk (IVW_FE: OR = 1.98, for per 1-SD unit increase in leptin level; 95% CI, 1.29– 3.06; p = 1.97E−03; Figure 2; Table 2)

Read more

Summary

Introduction

Schizophrenia (SCZ) is a major mental disease that represents a leading cause of impairment and burden worldwide [1]. Cardiovascular diseases (CVDs) and metabolic syndrome (MetS) are highly prevalent in patients with SCZ, contributing a large extent to dramatically increased mortality [2,3,4]. The high prevalence of CVDs in patients with SCZ may be partially attributed to unhealthy behaviors, including smoking, lack of physical activities, and dietary habits [5]. The. Leptin Level and Schizophrenia underlying mechanisms of metabolic abnormalities in patients with SCZ are complicated and still not fully understood. There is a great need to understand the mechanisms associated with metabolic abnormalities in SCZ patients. Observational studies that have supported the role of the leptin level in schizophrenia (SCZ) risk are conflicting. We performed a two-sample Mendelian randomization (MR) analysis to investigate whether the circulating leptin and soluble plasma leptin receptor (sOB-R) levels play a causal role in SCZ risk

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call